Stock DNA
Pharmaceuticals & Biotechnology
SEK 2,588 Million (Small Cap)
NA (Loss Making)
NA
0.00%
-0.32
-94.82%
7.29
Total Returns (Price + Dividend) 
Egetis Therapeutics AB for the last several years.
Risk Adjusted Returns v/s 
News
Egetis Therapeutics AB Reports Negative Financial Performance Amidst Strong Cash Position
Egetis Therapeutics AB, a small-cap player in the Pharmaceuticals & Biotechnology sector, has recently released its financial results for the quarter ending March 2025. The report indicates a challenging period for the company, with a net profit recorded at SEK -176 MM, reflecting negative financial performance.
Despite the downturn in profitability, Egetis Therapeutics AB has managed to maintain a robust cash position, with cash and equivalents reaching SEK 623.8 MM. This substantial liquidity may provide the company with the necessary resources to navigate its current challenges and invest in future growth opportunities.
Another noteworthy aspect of the financial report is the company's debt-equity ratio, which stands at -38.38%. This indicates that Egetis Therapeutics AB is debt-free, a factor that could enhance its financial stability...
Read More Announcements 
Corporate Actions 
Quality key factors 
Valuation key factors
Technicals key factors
Shareholding Snapshot
Shareholding Compare (%holding) 
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ
QoQ Growth in quarter ended Jun 2025 is 14.17% vs 17.59% in Mar 2025
QoQ Growth in quarter ended Jun 2025 is -23.37% vs 43.08% in Mar 2025
Annual Results Snapshot (Consolidated) - Dec'24
YoY Growth in year ended Dec 2024 is -19.97% vs 154.87% in Dec 2023
YoY Growth in year ended Dec 2024 is -5.11% vs -68.68% in Dec 2023






